A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14835 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von Jeffrey D Sharon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Objective
To study if galcanezumab is effective for vestibular migraine (VM).
Background
There are currently no placebo‐controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene–related peptide–targeted monoclonal antibody for VM.
Methods
This was a single site, prospective, double‐blind placebo controlled randomized clinical trial. Key inclusion criteria were as follows: participants aged 18–75 years with a diagnosis of VM or probable VM per Barany Society criteria. The primary outcome was change in VM‐PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) score, and secondary outcomes included change in DHI (Dizziness Handicap Inventory) score, and count of definite dizzy days (DDDs). Participants were randomized 1:1 to 3 months of treatment with galcanezumab or placebo via subcutaneous injection with a pre‐filled syringe, 240 mg the first month, and 120 mg for the second and third months.
Results
Forty participants were randomized, and 38 participants were in the modified intent to treat analysis. VM‐PATHI score was reduced 5.1 points (95% confidence interval [CI] −13.0 to 2.7) for placebo ( N = 21), and 14.8 points (95% CI −23.0 to −6.5) for galcanezumab ( N = 17), a difference of −9.6 (95% CI −20.7 to 1.5, p = 0.044). DHI dropped 8.3 points in the placebo arm (95% CI −15.0 to 1.6), and 22.0 points in the galcanezumab arm (95% CI −31.9 to −12.1), a difference of −13.7 (95% CI −20.4 to −8.5, p = 0.018). The count of DDDs per month dropped from 18 days (standard deviation [SD] 7.6) in the baseline month to 12.5 days (SD 11.2) in month 4 for those in the placebo arm, and from 17.9 days (SD 7.9) in the baseline month to 6.6 days (SD 7.3) in month 4 for those in the galcanezumab arm, a difference of −5.7 days (95% CI −10.7 to −0.7, p = 0.026). No serious adverse events were observed.
Conclusions
In this pilot study, galcanezumab was effective in treating VM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
- Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
ORCID-Profile: Jeffrey D Sharon, Ricky Chae
Förderung
- Eli Lilly and Company
Zitieren
APA
Sharon, J. D., Krauter, R., Chae, R., Gardi, A., Hum, M., Allen, I., & Levin, M. (2024). A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14835
Vancouver
Sharon JD, Krauter R, Chae R, Gardi A, Hum M, Allen I, et al. A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14835
BibTeX
@article{Sharon2024,
author = {Sharon, Jeffrey D and Krauter, Roseanne and Chae, Ricky and Gardi, Adam and Hum, Maxwell and Allen, Isabel and Levin, Morris},
title = {A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14835}
}
EUVIMED